SymBio Pharmaceuticals Limited (TYO:4582)

Japan · Delayed Price · Currency is JPY

56.00

0.00 (0.00%)

Oct 2, 2026, 3:30 PM JST

Market Cap	4.49B -30.3%
Revenue (ttm)	1.13B -37.7%
Net Income	-6.03B
EPS	-97.55
Shares Out	80.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,300
Open	56.00
Previous Close	56.00
Day's Range	55.00 - 56.00
52-Week Range	53.00 - 229.00
Beta	0.52
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 29, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan. [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 2005

Employees 91

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4582

Full Company Profile

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.70% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.

Financial Statements